Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy

Seizure

Volumn 20, Issue 5, 2011, Pages 387-394

  Haerian, B S ^a   Lim, K S ^a   Mohamed, E H M ^a   Tan, H J ^b   Tan, C T ^a   Raymond, A A ^b   Wong, C P ^c   Wong, S W ^b   Mohamed, Z ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

ABCB1; Antiepileptic drug; Epilepsy; P glycoprotein; Polymorphism; PXR

Indexed keywords

CARBAMAZEPINE; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; VALPROIC ACID;

ADULT; ALLELE; ARTICLE; CHINESE; DNA POLYMORPHISM; EPILEPSY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CHILD; EPILEPSY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RECEPTORS, STEROID; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 79955691266     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2011.01.008     Document Type: Article

References (45)

1. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46(2):224-35. (Pubitemid 40194666)
2. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
3. Löscher W, Potschka H. Blood - brain barrier active efflux transporters: ATP-binding cassette gene family. Epilepsia 2005:1-23.
4. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR1 (P-gp) gene family. Mol Cell Biol 1989;9:3808-20. (Pubitemid 19216274)
5. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50(1):1-23.
6. Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 2007;8(8):1075-80.
7. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8. (Pubitemid 30183327)
8. Haerian BS, Roslan H, Raymond AA, Tan CT, Zulkifli SZ, Lim KS, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010;19:339-46.
9. Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, Kaur H, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 2010.
10. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010;19(2):93-101.
11. Alpman A, Ozkinay F, Tekgul H, Gokben S, Pehlivan S, Schalling M, et al. Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resistant epilepsy. J Child Neurol 2010.
12. Zimprich F, Sunder-Olassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63:1087-9. (Pubitemid 39287922)
13. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, et al. Wholegenome patterns of common DNA variation in three human populations. Science 2005;307(5712):1072-9. (Pubitemid 40262106)
14. Frazer KA, Ballinger DG, Cox DR, et al. International-HapMap-Consortium: a second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449(7164):851-61. (Pubitemid 47598626)
15. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 2003;4:293-340. (Pubitemid 37392927)
16. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005;6(4):411-7. (Pubitemid 40916364)
17. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006;7(4):551-61. (Pubitemid 43891412)
18. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 2006;15(1):67-72. (Pubitemid 43092098)
19. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 2007;8(9):1151-8.
20. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res 2007;73(2):192-8. (Pubitemid 46331873)
21. Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Poon WS, et al. Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics 2009;10(5):723-32.
22. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet 2009;24(3):255-60.
23. Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, Cho JY, et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 2009;84(1):86-90.
24. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav 2009;14(1):78-82.
25. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005;6(4):369-83. (Pubitemid 41086769)
26. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006;130(2):341-8. [quiz 592].
27. Fanta S, Jönsson S, Karlsson MO, Niemi M, Holmberg C, Hoppu K, et al. Longterm changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J Clin Pharmacol 2010;50(5):581-97.
28. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008;73(11):1052-9.
29. Commission on Classification and Terminology of the International League Against Epilepsy; 1981.
30. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009:1-9.
31. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69(3):169-74. (Pubitemid 32225417)
32. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJD, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:437-50. (Pubitemid 34913526)
33. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004;14(7):1333-44. (Pubitemid 39029230)
34. Marchani EE, Watkins WS, Bulayeva K, Harpending HC, Jorde LB. Culture creates genetic structure in the Caucasus: autosomal, mitochondrial, and Y-chromosomal variation in Daghestan. BMC Genet 2008;9:47.
35. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, Shamovsky O, et al. Positive natural selection in the human lineage. Science 2006;312(5780):1614-20. (Pubitemid 43902654)
36. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363(16):1551-8.
37. Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 2006;7(4):349-65.
38. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43(4):365-85. (Pubitemid 34297175)
39. Elger CE, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008;12(4):501-39.
40. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51(4):345-9. (Pubitemid 32391490)
41. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320(1):331-43. (Pubitemid 46025748)
42. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Häsler R, et al. Nonresponse to antiepileptic pharmacotherapy is associated with the ABCC2-24C > T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009;19:353-62.
43. Szoeke C, Sills GJ, Kwan P, Petrovski S, Newton M, Hitiris N, et al. Multidrugresistance genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from International Pharmacogenetic Cohorts. Epilepsia 2009.
44. Yang HW, Liu HY, Liu X, Zhang DM, Liu YC, Liu XD, et al. Increased Pglycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett 2008;434(3):299-303.
45. Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 2006;149(3):250-60. (Pubitemid 44453425)